Niagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. The company is headquartered in Los Angeles, California and currently employs 117 full-time employees. The company went IPO on 2007-06-25. Its segments include Consumer Products, Ingredients segment, Analytical Reference Standards and Services and Pharmaceuticals. The Consumer Products segment provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors. The ingredients segment develops and commercializes proprietary-based ingredient technologies, including food-grade Niagen and pharmaceutical-grade Niagen, and supplies these ingredients as raw materials to the manufacturers of consumer products and outsourcing facilities. The Analytical Reference Standards and Services segment offer the supply of phytochemical reference standards and other research and development services. The Pharmaceutical segment focuses on the pharmaceutical development of its nicotinamide adenine dinucleotide (NAD) precursor portfolio for potential therapeutic applications in rare diseases.
Quel est le ratio P/E de Niagen Bioscience Inc (NAGE) ?
Le ratio P/E de Niagen Bioscience Inc est de 15.785
Qui est le CEO de Niagen Bioscience Inc ?
Mr. Robert Fried est le Chief Executive Officer de Niagen Bioscience Inc, il a rejoint l'entreprise depuis 2015.
Quelle est la performance du prix de l'action NAGE ?
Le prix actuel de NAGE est de $0, il a diminué de 100% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Niagen Bioscience Inc ?
Niagen Bioscience Inc appartient à l'industrie Consumer products et le secteur est Consumer Staples
Quel est la capitalisation boursière de Niagen Bioscience Inc ?
La capitalisation boursière actuelle de Niagen Bioscience Inc est de $NaN
Est-ce que Niagen Bioscience Inc est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 7 analystes ont établi des notations d'analystes pour Niagen Bioscience Inc, y compris 4 achat fort, 6 achat, 1 maintien, 0 vente et 4 vente forte